BRPI0519562A2 - construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea - Google Patents
construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁceaInfo
- Publication number
- BRPI0519562A2 BRPI0519562A2 BRPI0519562-4A BRPI0519562A BRPI0519562A2 BR PI0519562 A2 BRPI0519562 A2 BR PI0519562A2 BR PI0519562 A BRPI0519562 A BR PI0519562A BR PI0519562 A2 BRPI0519562 A2 BR PI0519562A2
- Authority
- BR
- Brazil
- Prior art keywords
- fviii
- proteinaceous construct
- vwf
- complex
- life
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 238000001727 in vivo Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 5
- 102100036537 von Willebrand factor Human genes 0.000 abstract 5
- 229960001134 von willebrand factor Drugs 0.000 abstract 5
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 238000010276 construction Methods 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000007849 functional defect Effects 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63924404P | 2004-12-27 | 2004-12-27 | |
| US66837805P | 2005-04-04 | 2005-04-04 | |
| US67190105P | 2005-04-15 | 2005-04-15 | |
| US68508605P | 2005-05-26 | 2005-05-26 | |
| PCT/US2005/046879 WO2006071801A2 (en) | 2004-12-27 | 2005-12-23 | Polymer-von willebrand factor-conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519562A2 true BRPI0519562A2 (pt) | 2009-01-27 |
Family
ID=36540284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519562-4A BRPI0519562A2 (pt) | 2004-12-27 | 2005-12-23 | construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7884075B2 (enExample) |
| EP (1) | EP1835938B1 (enExample) |
| JP (2) | JP5022231B2 (enExample) |
| KR (1) | KR20070092754A (enExample) |
| CN (1) | CN101163506B (enExample) |
| AU (1) | AU2005322067B8 (enExample) |
| BR (1) | BRPI0519562A2 (enExample) |
| CA (1) | CA2591852A1 (enExample) |
| DK (1) | DK1835938T3 (enExample) |
| ES (1) | ES2434035T3 (enExample) |
| IL (1) | IL183634A (enExample) |
| MX (1) | MX2007007877A (enExample) |
| PL (1) | PL1835938T3 (enExample) |
| PT (1) | PT1835938E (enExample) |
| WO (1) | WO2006071801A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプｒａｍのチエツク方法 |
| CA2591852A1 (en) | 2004-12-27 | 2006-07-06 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
| US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
| ES2531934T3 (es) | 2006-09-01 | 2015-03-20 | Novo Nordisk Health Care Ag | Glicoproteínas modificadas |
| JP5876208B2 (ja) * | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体 |
| WO2008082669A2 (en) | 2006-12-27 | 2008-07-10 | Nektar Therapeutics Al, Corporation | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
| ES2539284T3 (es) * | 2007-05-18 | 2015-06-29 | Baxter International Inc. | Procedimiento de producción de VWF maduro a partir del propéptido de VWF |
| CA2690218C (en) * | 2007-06-13 | 2017-02-28 | Csl Behring Gmbh | Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| EP2173383B1 (en) * | 2007-06-26 | 2017-08-09 | Baxalta GmbH | Hydrolysable polymeric fmoc-linker |
| KR20100095441A (ko) * | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법 |
| KR101627157B1 (ko) | 2007-12-27 | 2016-06-03 | 박스알타 인코퍼레이티드 | 샘플 내의 재조합 단백질로부터 혈장-유래 단백질의 분별 방법 |
| CA2710518C (en) | 2007-12-27 | 2018-07-17 | Baxter International Inc. | Method and compositions for specifically detecting physiologically acceptable polymer molecules |
| SG187410A1 (en) | 2007-12-28 | 2013-02-28 | Baxter Int | Recombinant vwf formulations |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| CA2710567A1 (en) | 2007-12-31 | 2009-07-16 | Baxter Healthcare S.A. | Transgenic non-human animals expressing human blood clotting factors |
| AU2009245734A1 (en) * | 2008-05-06 | 2009-11-12 | Octapharma Ag | Complex comprising both heparin binding proteins and heparin-hydroxyalkyl starch conjugates |
| AU2009262476C1 (en) * | 2008-06-24 | 2016-06-02 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
| AU2009274738B2 (en) * | 2008-07-23 | 2012-12-13 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
| US8575102B2 (en) * | 2008-08-01 | 2013-11-05 | Nektar Therapeutics | Conjugates having a releasable linkage |
| MX2011004085A (es) | 2008-10-17 | 2011-09-27 | Baxter International | Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua. |
| US8586710B2 (en) * | 2008-10-20 | 2013-11-19 | Usv, Ltd. | Process for gram scale production of PEG-r-metHuG-CSF |
| US9274122B2 (en) | 2008-10-21 | 2016-03-01 | Baxalta Incorporated | Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation) |
| TWI593421B (zh) | 2008-10-21 | 2017-08-01 | 巴克斯歐塔公司 | 凍乾的重組ｖｗｆ調配物 |
| CA2746125C (en) * | 2008-12-11 | 2017-07-11 | Baxter International Inc. | Detection of physiologically acceptable polymer molecules using near infrared spectroscopy |
| CN102497884A (zh) | 2009-07-27 | 2012-06-13 | 巴克斯特国际公司 | 凝血蛋白缀合物 |
| NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| WO2011012850A2 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US20110072524A1 (en) * | 2009-08-04 | 2011-03-24 | Baxter International Inc. | Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A |
| DK2467399T3 (en) * | 2009-08-20 | 2017-01-23 | Baxalta Inc | Purification of vWF for increased removal of non-lipid-enveloped viruses |
| WO2011028228A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| PT2499165T (pt) | 2009-11-13 | 2016-10-28 | Grifols Therapeutics Inc | Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| KR102172133B1 (ko) | 2010-07-30 | 2020-11-02 | 박스알타 인코퍼레이티드 | 옥심 결합용 친핵성 촉매 |
| KR101309566B1 (ko) * | 2010-12-10 | 2013-09-17 | 포항공과대학교 산학협력단 | 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법 |
| PT2654794T (pt) | 2010-12-22 | 2020-06-11 | Baxalta Inc | Materiais e métodos para conjugação de um derivado de ácido gordo solúvel em água a uma proteína |
| WO2012166622A1 (en) | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic proteins with increased half-life and methods of preparing same |
| RU2680402C2 (ru) * | 2011-06-10 | 2019-02-21 | Бакстер Интернэшнл Инк. | Лечение нарушений свертываемости крови путем введения рекомбинантного фв |
| CN104271150A (zh) * | 2012-01-12 | 2015-01-07 | 比奥根艾迪克Ma公司 | 嵌合因子viii多肽及其用途 |
| DK2814502T3 (en) | 2012-02-15 | 2017-12-18 | Csl Behring Gmbh | Von Willebrand Factor variants with improved Factor VIII binding affinity |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| ES2935489T3 (es) | 2012-02-15 | 2023-03-07 | Bioverativ Therapeutics Inc | Composiciones de factor VIII y métodos de preparación y uso de las mismas |
| AU2013204754C1 (en) | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| NZ703366A (en) * | 2012-07-11 | 2018-03-23 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
| ES2657291T3 (es) * | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| US10947269B2 (en) * | 2013-08-08 | 2021-03-16 | Bioverativ Therapeutics Inc. | Purification of chimeric FVIII molecules |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| PL3091997T3 (pl) | 2014-01-10 | 2023-01-02 | Bioverativ Therapeutics Inc. | Białka chimeryczne czynnika viii i ich zastosowania |
| AU2015274238B2 (en) | 2014-06-13 | 2020-11-05 | Csl Limited | Improved production of recombinant von Willebrand factor in a bioreactor |
| CN106659771B (zh) | 2014-07-02 | 2021-09-24 | 康诺贝林伦瑙有限公司 | 修饰的von Willebrand因子 |
| CN104491917B (zh) * | 2014-12-30 | 2018-01-09 | 广州市拜特凇医药科技有限公司 | 一种含有peg或其衍生物的生物材料 |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| CN107810194B (zh) | 2015-05-22 | 2021-10-08 | 康诺贝林伦瑙有限公司 | 用于制备经修饰的血管性血友病因子的方法 |
| CN107787328B (zh) | 2015-05-22 | 2021-08-06 | 康诺贝林伦瑙有限公司 | 用于治疗血友病的截短的血管性血友病因子多肽 |
| JP2015155469A (ja) * | 2015-06-01 | 2015-08-27 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 第ｆｖｉｉｉ因子ポリマー結合体 |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| RU2018128582A (ru) | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| RU2018128613A (ru) | 2016-01-07 | 2020-02-07 | Цсл Беринг Ленгнау Аг | Мутированный фактор фон виллебранда |
| CA3043397A1 (en) | 2016-11-11 | 2018-05-17 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| KR20190085021A (ko) | 2016-11-11 | 2019-07-17 | 체에스엘 베링 렝나우 아게 | 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드 |
| IL319473A (en) | 2016-12-02 | 2025-05-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| DK3648787T3 (da) | 2017-07-07 | 2025-01-20 | Takeda Pharmaceuticals Co | Behandling af patienter, der har svær von willebrand-sygdom og får foretaget elektiv kirurgi, ved administration af rekombinant vwf |
| CN111436193A (zh) | 2017-07-07 | 2020-07-21 | 百深公司 | 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血 |
| WO2019038350A1 (en) | 2017-08-23 | 2019-02-28 | Csl Behring Gmbh | PROCESS FOR VIRAL FILTERING OF VON WILLEBRAND FACTOR |
| JP2018115170A (ja) * | 2018-03-02 | 2018-07-26 | バクスアルタ ゲーエムベーハー | 第ｆｖｉｉｉ因子ポリマー結合体 |
| AU2019240135B2 (en) | 2018-03-21 | 2024-10-03 | Takeda Pharmaceutical Company Limited | Separation of VWF and VWF propeptide by chromatographic methods |
| DK3793588T3 (da) | 2018-05-18 | 2025-06-16 | Bioverativ Therapeutics Inc | Fremgangsmåder til behandling af hæmofili a |
| EP3917557A1 (en) | 2019-02-01 | 2021-12-08 | Takeda Pharmaceutical Company Limited | Methods of prophylactic treatment using recombinant vwf (rvwf) |
| WO2021050718A1 (en) | 2019-09-11 | 2021-03-18 | Baxalta Incorporated | Methods of treatment related to complexes of von willebrand factor and complement c1q |
| KR20220150303A (ko) | 2020-02-04 | 2022-11-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU591671B2 (en) | 1985-04-11 | 1989-12-14 | Children's Medical Center Corporation | Von willebrand factor |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE4001451A1 (de) | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| AU2297792A (en) | 1991-06-28 | 1993-01-25 | Rhone-Poulenc Rorer International (Holdings) Inc. | Therapeutic polypeptides based on von willebrand factor |
| US6037452A (en) * | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| MX9306133A (es) | 1992-10-02 | 1994-04-29 | Kabi Pharmacia Ab | Composicion que comprende una formulacion del factor de coagulacion viii, proceso para su preparacion y uso de un surfactante como estabilizador. |
| US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
| AU6029594A (en) * | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US6127153A (en) | 1995-06-07 | 2000-10-03 | Neose Technologies, Inc. | Method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and gene encoding a polyglycosyltransferase |
| SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6005077A (en) | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| US6562781B1 (en) | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| AT405740B (de) | 1996-12-13 | 1999-11-25 | Immuno Ag | Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen |
| AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| EP0985697B1 (en) | 1998-03-24 | 2006-01-04 | Nof Corporation | Oxirane derivatives and process for producing the same |
| AT407750B (de) | 1999-02-19 | 2001-05-25 | Immuno Ag | Verfahren zur herstellung einer vwf-präparation |
| CZ307715B6 (cs) | 1999-02-22 | 2019-03-06 | University Of Connecticut | Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu |
| AU6357900A (en) | 1999-07-20 | 2001-02-05 | Amgen, Inc. | Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods |
| SE515295C2 (sv) | 1999-11-23 | 2001-07-09 | Medicarb Ab | Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat |
| AUPR610501A0 (en) | 2001-07-04 | 2001-07-26 | Smart Drug Systems Inc | Treatment of parasitic disease |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| EP1446438A2 (en) | 2001-11-07 | 2004-08-18 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| SI1596887T1 (sl) * | 2003-02-26 | 2022-05-31 | Nektar Therapeutics | Konjugati polimer-del faktorja VIII |
| US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| WO2005032581A2 (en) | 2003-10-07 | 2005-04-14 | Novo Nordisk Health Care Ag | Hybrid molecules having factor vii/viia activity |
| US9539337B2 (en) | 2003-12-10 | 2017-01-10 | Nektar Therapeutics | Compositions comprising two different populations of polymer-active agent conjugates |
| CA2591852A1 (en) * | 2004-12-27 | 2006-07-06 | Baxter International Inc. | Polymer-von willebrand factor-conjugates |
-
2005
- 2005-12-23 CA CA002591852A patent/CA2591852A1/en not_active Abandoned
- 2005-12-23 JP JP2007548552A patent/JP5022231B2/ja not_active Expired - Lifetime
- 2005-12-23 ES ES05855442T patent/ES2434035T3/es not_active Expired - Lifetime
- 2005-12-23 DK DK05855442.9T patent/DK1835938T3/da active
- 2005-12-23 KR KR1020077017261A patent/KR20070092754A/ko not_active Withdrawn
- 2005-12-23 CN CN2005800445983A patent/CN101163506B/zh not_active Expired - Lifetime
- 2005-12-23 US US11/317,582 patent/US7884075B2/en active Active
- 2005-12-23 BR BRPI0519562-4A patent/BRPI0519562A2/pt not_active IP Right Cessation
- 2005-12-23 PL PL05855442T patent/PL1835938T3/pl unknown
- 2005-12-23 WO PCT/US2005/046879 patent/WO2006071801A2/en not_active Ceased
- 2005-12-23 PT PT58554429T patent/PT1835938E/pt unknown
- 2005-12-23 AU AU2005322067A patent/AU2005322067B8/en not_active Expired
- 2005-12-23 MX MX2007007877A patent/MX2007007877A/es active IP Right Grant
- 2005-12-23 EP EP05855442.9A patent/EP1835938B1/en not_active Expired - Lifetime
-
2007
- 2007-06-04 IL IL183634A patent/IL183634A/en active IP Right Grant
-
2011
- 2011-01-14 US US13/007,208 patent/US8076463B2/en not_active Expired - Lifetime
- 2011-11-28 US US13/305,334 patent/US8357779B2/en not_active Expired - Lifetime
-
2012
- 2012-03-30 JP JP2012081700A patent/JP5715983B2/ja not_active Expired - Lifetime
- 2012-12-21 US US13/724,831 patent/US8835388B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005322067A1 (en) | 2006-07-06 |
| JP2008525491A (ja) | 2008-07-17 |
| PT1835938E (pt) | 2013-11-06 |
| JP2012126750A (ja) | 2012-07-05 |
| EP1835938B1 (en) | 2013-08-07 |
| US8357779B2 (en) | 2013-01-22 |
| EP1835938A2 (en) | 2007-09-26 |
| CN101163506B (zh) | 2012-09-26 |
| US20120135462A1 (en) | 2012-05-31 |
| AU2005322067B8 (en) | 2012-07-26 |
| PL1835938T3 (pl) | 2014-01-31 |
| US20130190242A1 (en) | 2013-07-25 |
| US20060160948A1 (en) | 2006-07-20 |
| AU2005322067B2 (en) | 2012-07-05 |
| ES2434035T3 (es) | 2013-12-13 |
| HK1105276A1 (en) | 2008-02-06 |
| KR20070092754A (ko) | 2007-09-13 |
| JP5022231B2 (ja) | 2012-09-12 |
| US8076463B2 (en) | 2011-12-13 |
| JP5715983B2 (ja) | 2015-05-13 |
| US7884075B2 (en) | 2011-02-08 |
| US20110111455A1 (en) | 2011-05-12 |
| MX2007007877A (es) | 2007-08-21 |
| IL183634A (en) | 2012-02-29 |
| CN101163506A (zh) | 2008-04-16 |
| IL183634A0 (en) | 2007-09-20 |
| DK1835938T3 (da) | 2013-11-04 |
| WO2006071801A3 (en) | 2007-08-16 |
| US8835388B2 (en) | 2014-09-16 |
| CA2591852A1 (en) | 2006-07-06 |
| WO2006071801A2 (en) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0519562A2 (pt) | construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea | |
| ES2451651T3 (es) | Composiciones de liberación inmediata para el tratamiento de daños tisulares | |
| JP2008525491A5 (enExample) | ||
| BRPI0720282B8 (pt) | construção proteica, composição farmacêutica, e, kit | |
| Lorentz et al. | Engineered aprotinin for improved stability of fibrin biomaterials | |
| RU2008145084A (ru) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo | |
| DK2717905T3 (en) | TREATMENT OF COAGULATION DISEASE BY ADMINISTRATION OF RECOMBINANT VWF | |
| EP2130549B1 (en) | Solid fibrinogen preparation | |
| BRPI0109494B8 (pt) | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii | |
| PE20091405A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| JP6717747B2 (ja) | フィブリノゲン結合ペプチドを含むペプチドデンドリマー | |
| PT2440239T (pt) | Composições de hemoglobina | |
| Nam et al. | Synergistic effects of laminin-1 peptides, VEGF and FGF9 on salivary gland regeneration | |
| NO20015584D0 (no) | Lantidsvarende insulintrofiske peptider | |
| DE602005019853D1 (de) | Pharmazeutische Zusammensetzung mit lyophilisiertem rekombinantem Faktor VIII ohne Albumin als Stabilisator | |
| PT1559431E (pt) | Composição farmacêutica para derivados peptídicos de trombina. | |
| BRPI0514411A (pt) | formulação, e, método de produzir uma formulação | |
| DE50110182D1 (de) | Verwendung von fibrin/fibrinogenpeptiden und -proteinen zur herstellung eines arzneimittels | |
| ITTO20010804A1 (it) | Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl | |
| ES2331970T3 (es) | Procedimiento para determinar el efecto antiinflamatorio de un peptido. | |
| ES2913934T3 (es) | Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias | |
| Blombäck | Travels with fibrinogen | |
| US12214076B2 (en) | Drug delivery vehicles for atherosclerosis nanomedicine | |
| CN101247822B (zh) | 含有epo衍生物的血液相关疾病的治疗剂 | |
| US20100099602A1 (en) | Pharmaceutical compositions and methods of use for the prevention and treatment of hypoxic injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B25G | Requested change of headquarter approved |
Owner name: BAXTER INTERNATIONAL INC (US) , BAXTER HEALTHCARE Free format text: ENDERECO DO 2O DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110115944/RJ DE 11/11/2011. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/755 (2006.01), A61K 47/60 (2017.01), C07K |